Everything You Wanted to Know About the COVID-19 Vaccine, in One Place
Article by Shannon Palus published online at Slate.com December 11, 2020.
The Pfizer-BioNtech vaccine was just granted the first emergency use authorization (EUA) in the U.S., allowing the company to start shipping the first couple of million doses. A second vaccine candidate developed by Moderna will be reviewed by the special FDA advisory panel on December 17th. We have questions. Here is a nice summary that checks off most of the right boxes from Slate. Stay tuned as further details emerge and send me any specific questions you might have.
Today’s bite-sized, handpicked selection of important news, information or science for all who want to know where this epidemic is going and what we should do.
2 thoughts on “Top pick of the day: Sunday”
I have a lot of questions too. I just feel like I need to see more data. Experts are saying that the vaccine may not prevent infection with the virus, or asymptomatic cases, just severe symptoms of COVID 19. We know a good bit about people with asymptomatic or mild cases having serious complications later on e.g. Big Ten football. It’s possible to still spread the virus to others after getting the vaccine. I’m just struggling to see how it’s worth it to take the vaccine vs. just continuing to quarantine. What are your thoughts?
Great comments and questions Cara. You have hit the real hot button issues. We don’t know a) efficacy after 6 weeks and later, b) efficacy for asymptomatic disease and c) whether vaccine prevents death. I’m going to address all your questions on Wednesday. Thanks again.